BEAM
Price
$35.41
Change
+$0.86 (+2.49%)
Updated
Jan 14 closing price
Capitalization
3.59B
47 days until earnings call
Intraday BUY SELL Signals
GLPG
Price
$34.12
Change
+$0.87 (+2.62%)
Updated
Jan 14 closing price
Capitalization
2.24B
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs GLPG

Header iconBEAM vs GLPG Comparison
Open Charts BEAM vs GLPGBanner chart's image
Beam Therapeutics
Price$35.41
Change+$0.86 (+2.49%)
Volume$2.34M
Capitalization3.59B
Galapagos
Price$34.12
Change+$0.87 (+2.62%)
Volume$223.91K
Capitalization2.24B
BEAM vs GLPG Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. GLPG commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and GLPG is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (BEAM: $35.41 vs. GLPG: $34.12)
Brand notoriety: BEAM and GLPG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 122% vs. GLPG: 197%
Market capitalization -- BEAM: $3.59B vs. GLPG: $2.24B
BEAM [@Biotechnology] is valued at $3.59B. GLPG’s [@Biotechnology] market capitalization is $2.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileGLPG’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • GLPG’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than GLPG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while GLPG’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 4 bearish.
  • GLPG’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, GLPG is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а +22.40% price change this week, while GLPG (@Biotechnology) price change was +3.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

GLPG is expected to report earnings on Feb 24, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($3.59B) has a higher market cap than GLPG($2.24B). BEAM YTD gains are higher at: 27.742 vs. GLPG (4.343). GLPG has higher annual earnings (EBITDA): -133.96M vs. BEAM (-434.55M). GLPG has more cash in the bank: 3.05B vs. BEAM (1.08B). GLPG has less debt than BEAM: GLPG (7.5M) vs BEAM (151M). GLPG has higher revenues than BEAM: GLPG (287M) vs BEAM (55.7M).
BEAMGLPGBEAM / GLPG
Capitalization3.59B2.24B161%
EBITDA-434.55M-133.96M324%
Gain YTD27.7424.343639%
P/E RatioN/A53.70-
Revenue55.7M287M19%
Total Cash1.08B3.05B35%
Total Debt151M7.5M2,013%
FUNDAMENTALS RATINGS
BEAM vs GLPG: Fundamental Ratings
BEAM
GLPG
OUTLOOK RATING
1..100
7823
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
83
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
3849
P/E GROWTH RATING
1..100
10062
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (37) in the null industry is somewhat better than the same rating for GLPG (83) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than GLPG’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as GLPG (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to GLPG’s over the last 12 months.

GLPG's SMR Rating (95) in the Biotechnology industry is in the same range as BEAM (97) in the null industry. This means that GLPG’s stock grew similarly to BEAM’s over the last 12 months.

BEAM's Price Growth Rating (38) in the null industry is in the same range as GLPG (49) in the Biotechnology industry. This means that BEAM’s stock grew similarly to GLPG’s over the last 12 months.

GLPG's P/E Growth Rating (62) in the Biotechnology industry is somewhat better than the same rating for BEAM (100) in the null industry. This means that GLPG’s stock grew somewhat faster than BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMGLPG
RSI
ODDS (%)
Bearish Trend 3 days ago
79%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
76%
Momentum
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
64%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
59%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
56%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 14 days ago
63%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
N/A
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
63%
Aroon
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
GLPG
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VEVIX47.440.37
+0.79%
Victory Sycamore Established Value I
TFFAX9.690.03
+0.31%
Templeton Foreign Adv
HSLSX44.080.09
+0.20%
Hartford Small Cap Growth R4
BUIIX24.73-0.10
-0.40%
Buffalo International Institutional
RYCHX191.82-2.07
-1.07%
Rydex Technology C

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+2.49%
CRSP - BEAM
71%
Closely correlated
+1.26%
RXRX - BEAM
62%
Loosely correlated
+3.41%
NTLA - BEAM
61%
Loosely correlated
+2.39%
PRME - BEAM
59%
Loosely correlated
+3.61%
SYRE - BEAM
57%
Loosely correlated
+5.17%
More

GLPG and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLPG has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if GLPG jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLPG
1D Price
Change %
GLPG100%
+2.62%
VCYT - GLPG
43%
Loosely correlated
-1.39%
AXON - GLPG
35%
Loosely correlated
-1.92%
MRNA - GLPG
35%
Loosely correlated
+2.47%
NEUP - GLPG
33%
Poorly correlated
-3.12%
BEAM - GLPG
33%
Poorly correlated
+2.49%
More